Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Biol Chem ; 290(23): 14361-80, 2015 Jun 05.
Artículo en Inglés | MEDLINE | ID: mdl-25878248

RESUMEN

Abnormal accumulation of undigested macromolecules, often disease-specific, is a major feature of lysosomal and neurodegenerative disease and is frequently attributed to defective autophagy. The mechanistic underpinnings of the autophagy defects are the subject of intense research, which is aided by genetic disease models. To gain an improved understanding of the pathways regulating defective autophagy specifically in juvenile neuronal ceroid lipofuscinosis (JNCL or Batten disease), a neurodegenerative disease of childhood, we developed and piloted a GFP-microtubule-associated protein 1 light chain 3 (GFP-LC3) screening assay to identify, in an unbiased fashion, genotype-sensitive small molecule autophagy modifiers, employing a JNCL neuronal cell model bearing the most common disease mutation in CLN3. Thapsigargin, a sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA) Ca(2+) pump inhibitor, reproducibly displayed significantly more activity in the mouse JNCL cells, an effect that was also observed in human-induced pluripotent stem cell-derived JNCL neural progenitor cells. The mechanism of thapsigargin sensitivity was Ca(2+)-mediated, and autophagosome accumulation in JNCL cells could be reversed by Ca(2+) chelation. Interrogation of intracellular Ca(2+) handling highlighted alterations in endoplasmic reticulum, mitochondrial, and lysosomal Ca(2+) pools and in store-operated Ca(2+) uptake in JNCL cells. These results further support an important role for the CLN3 protein in intracellular Ca(2+) handling and in autophagic pathway flux and establish a powerful new platform for therapeutic screening.


Asunto(s)
Calcio/metabolismo , Glicoproteínas de Membrana/metabolismo , Chaperonas Moleculares/metabolismo , Células-Madre Neurales/patología , Lipofuscinosis Ceroideas Neuronales/patología , Animales , Autofagia/efectos de los fármacos , Línea Celular , Células Cultivadas , Evaluación Preclínica de Medicamentos , Humanos , Glicoproteínas de Membrana/genética , Ratones , Chaperonas Moleculares/genética , Mutación , Células-Madre Neurales/metabolismo , Lipofuscinosis Ceroideas Neuronales/tratamiento farmacológico , Lipofuscinosis Ceroideas Neuronales/genética , Lipofuscinosis Ceroideas Neuronales/metabolismo , Transducción de Señal/efectos de los fármacos
2.
J Clin Invest ; 124(2): 644-55, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24401270

RESUMEN

T cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer that is frequently associated with activating mutations in NOTCH1 and dysregulation of MYC. Here, we performed 2 complementary screens to identify FDA-approved drugs and drug-like small molecules with activity against T-ALL. We developed a zebrafish system to screen small molecules for toxic activity toward MYC-overexpressing thymocytes and used a human T-ALL cell line to screen for small molecules that synergize with Notch inhibitors. We identified the antipsychotic drug perphenazine in both screens due to its ability to induce apoptosis in fish, mouse, and human T-ALL cells. Using ligand-affinity chromatography coupled with mass spectrometry, we identified protein phosphatase 2A (PP2A) as a perphenazine target. T-ALL cell lines treated with perphenazine exhibited rapid dephosphorylation of multiple PP2A substrates and subsequent apoptosis. Moreover, shRNA knockdown of specific PP2A subunits attenuated perphenazine activity, indicating that PP2A mediates the drug's antileukemic activity. Finally, human T-ALLs treated with perphenazine exhibited suppressed cell growth and dephosphorylation of PP2A targets in vitro and in vivo. Our findings provide a mechanistic explanation for the recurring identification of phenothiazines as a class of drugs with anticancer effects. Furthermore, these data suggest that pharmacologic PP2A activation in T-ALL and other cancers driven by hyperphosphorylated PP2A substrates has therapeutic potential.


Asunto(s)
Apoptosis , Fenotiazinas/química , Leucemia-Linfoma Linfoblástico de Células T Precursoras/metabolismo , Leucemia-Linfoma Linfoblástico de Células T Precursoras/patología , Proteína Fosfatasa 2/metabolismo , Animales , Animales Modificados Genéticamente , Línea Celular Tumoral , Supervivencia Celular , Cromatografía de Afinidad , Modelos Animales de Enfermedad , Antagonistas de Dopamina/química , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Espectrometría de Masas , Ratones , Perfenazina/química , Fosforilación , Pigmentación , Proteómica , Receptores Notch/metabolismo , Factores de Tiempo , Pez Cebra
3.
ACS Chem Neurosci ; 3(2): 120-128, 2012 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-22754608

RESUMEN

Modulation of histone modifications in the brain may represent a new mechanism for brain disorder therapy. Post-translational modifications of histones regulate gene expression, affecting major cellular processes such as proliferation, differentiation, and function. An important enzyme involved in one of these histone modifications is lysine specific demethylase 1 (LSD1). This enzyme is flavin-dependent and exhibits homology to amine oxidases. Parnate (2-phenylcyclopropylamine (2-PCPA); tranylcypromine) is a potent inhibitor of monoamine oxidases and derivatives of 2-PCPA have been used for development of selective LSD1 inhibitors based on the ability to form covalent adducts with flavin adenine dinucleotide (FAD). Here we report the synthesis and in vitro characterization of LSD1 inhibitors that bond covalently to FAD. The two most potent and selective inhibitors were used to demonstrate brain penetration when administered systemically to rodents. First, radiosynthesis of a positron-emitting analog was used to obtain preliminary bio-distribution data and whole brain time-activity curves. Second, we demonstrate that this series of LSD1 inhibitors is capable of producing a cognitive effect in a mouse model. By using a memory formation paradigm, novel object recognition, we show that LSD1 inhibition can abolish long-term memory formation without affecting short-term memory, providing further evidence for the importance of reversible histone methylation in the function of the nervous system.

4.
Proc Natl Acad Sci U S A ; 107(43): 18342-7, 2010 Oct 26.
Artículo en Inglés | MEDLINE | ID: mdl-20937901

RESUMEN

Discovery of molecular mechanisms and chemical compounds that enhance neuronal regeneration can lead to development of therapeutics to combat nervous system injuries and neurodegenerative diseases. By combining high-throughput microfluidics and femtosecond laser microsurgery, we demonstrate for the first time large-scale in vivo screens for identification of compounds that affect neurite regeneration. We performed thousands of microsurgeries at single-axon precision in the nematode Caenorhabditis elegans at a rate of 20 seconds per animal. Following surgeries, we exposed the animals to a hand-curated library of approximately one hundred small molecules and identified chemicals that significantly alter neurite regeneration. In particular, we found that the PKC kinase inhibitor staurosporine strongly modulates regeneration in a concentration- and neuronal type-specific manner. Two structurally unrelated PKC inhibitors produce similar effects. We further show that regeneration is significantly enhanced by the PKC activator prostratin.


Asunto(s)
Regeneración Nerviosa/efectos de los fármacos , Animales , Axones/efectos de los fármacos , Axones/fisiología , Caenorhabditis elegans/efectos de los fármacos , Caenorhabditis elegans/fisiología , Evaluación Preclínica de Medicamentos , Terapia por Láser/métodos , Microfluídica/métodos , Microcirugia/métodos , Procedimientos Neuroquirúrgicos/métodos , Proteína Quinasa C/antagonistas & inhibidores , Inhibidores de Proteínas Quinasas/química , Inhibidores de Proteínas Quinasas/farmacología , Estaurosporina/farmacología , Factores de Tiempo
5.
ACS Med Chem Lett ; 2(1): 39-42, 2010 Oct 08.
Artículo en Inglés | MEDLINE | ID: mdl-21874153

RESUMEN

Carboxylic acids with known central nervous system and histone deacetylase (HDAC) inhibitory activities were converted to hydroxamic acids and tested using a suite of in vitro biochemical assays with recombinant HDAC isoforms, cell based assays in human cervical carcinoma Hela cells and primary cultures from mouse forebrain, and a whole animal (Xenopus laevis) developmental assay. Relative to the parent carboxylic acids, two of these analogs exhibited enhanced potency, and one analog showed altered HDAC isoform selectivity and in vivo activity in the Xenopus assay. We discuss potential uses of these novel hydroxamic acids in studies aimed at determining the utility of HDAC inhibitors as memory enhancers and mood stabilizers.

6.
Artículo en Inglés | MEDLINE | ID: mdl-19965065

RESUMEN

Compound screening is a powerful tool to identify new therapeutic targets, drug leads, and elucidate the fundamental mechanisms of biological processes. We report here the results of the first in vivo small-molecule screens for compounds enhancing neuronal regeneration. These screens are enabled by the microfluidic devices we have developed for C. elegans. The devices enable rapid and repeatable animal immobilization which allows high-throughput and precise surgery. Following surgery, animals are exposed to the contents of a small-molecule library and assayed for neuronal regeneration. Using this screening method we have identified several compounds that enhance neural regeneration in vivo.


Asunto(s)
Bioensayo/instrumentación , Caenorhabditis elegans/efectos de los fármacos , Evaluación Preclínica de Medicamentos/instrumentación , Técnicas Analíticas Microfluídicas/instrumentación , Regeneración Nerviosa/efectos de los fármacos , Fármacos Neuroprotectores/administración & dosificación , Animales , Caenorhabditis elegans/fisiología , Diseño de Equipo , Análisis de Falla de Equipo , Regeneración Nerviosa/fisiología
7.
Blood ; 114(19): 4233-42, 2009 Nov 05.
Artículo en Inglés | MEDLINE | ID: mdl-19729518

RESUMEN

The tightly regulated production of distinct erythrocyte protein 4.1R isoforms involves differential splicing of 3 mutually exclusive first exons (1A, 1B, 1C) to the alternative 3' splice sites (ss) of exon 2'/2. Here, we demonstrate that exon 1 and 2'/2 splicing diversity is regulated by a transcription-coupled splicing mechanism. We also implicate distinctive regulatory elements that promote the splicing of exon 1A to the distal 3' ss and exon 1B to the proximal 3' ss in murine erythroleukemia cells. A hybrid minigene driven by cytomegalovirus promoter mimicked 1B-promoter-driven splicing patterns but differed from 1A-promoter-driven splicing patterns, suggesting that promoter identity affects exon 2'/2 splicing. Furthermore, splicing factor SF2/ASF ultraviolet (UV) cross-linked to the exon 2'/2 junction CAGAGAA, a sequence that overlaps the distal U2AF(35)-binding 3' ss. Consequently, depletion of SF2/ASF allowed exon 1B to splice to the distal 3' ss but had no effect on exon 1A splicing. These findings identify for the first time that an SF2/ASF binding site also can serve as a 3' ss in a transcript-dependent manner. Taken together, our results suggest that 4.1R gene expression involves transcriptional regulation coupled with a complex splicing regulatory network.


Asunto(s)
Empalme Alternativo , Proteínas Sanguíneas/genética , Proteínas del Citoesqueleto/genética , Proteínas de la Membrana/genética , Regiones no Traducidas 5' , Animales , Secuencia de Bases , Sitios de Unión/genética , Proteínas Sanguíneas/biosíntesis , Línea Celular , Proteínas del Citoesqueleto/biosíntesis , ADN Polimerasa II/metabolismo , Cartilla de ADN/genética , Exones , Humanos , Leucemia Eritroblástica Aguda/genética , Leucemia Eritroblástica Aguda/metabolismo , Proteínas de la Membrana/biosíntesis , Ratones , Proteínas de Microfilamentos , Modelos Genéticos , Datos de Secuencia Molecular , Proteínas Nucleares/metabolismo , Regiones Promotoras Genéticas , Isoformas de Proteínas/biosíntesis , Isoformas de Proteínas/genética , Proteínas de Unión al ARN/metabolismo , Ribonucleoproteínas/metabolismo , Factores de Empalme Serina-Arginina , Factor de Empalme U2AF , Distribución Tisular , Transcripción Genética , Activación Transcripcional , Células Tumorales Cultivadas
8.
BMC Immunol ; 9: 44, 2008 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-18673556

RESUMEN

BACKGROUND: The differentiation of naive T and B cells into memory lymphocytes is essential for immunity to pathogens. Therapeutic manipulation of this cellular differentiation program could improve vaccine efficacy and the in vitro expansion of memory cells. However, chemical screens to identify compounds that induce memory differentiation have been limited by 1) the lack of reporter-gene or functional assays that can distinguish naive and memory-phenotype T cells at high throughput and 2) a suitable cell-line representative of naive T cells. RESULTS: Here, we describe a method for gene-expression based screening that allows primary naive and memory-phenotype lymphocytes to be discriminated based on complex genes signatures corresponding to these differentiation states. We used ligation-mediated amplification and a fluorescent, bead-based detection system to quantify simultaneously 55 transcripts representing naive and memory-phenotype signatures in purified populations of human T cells. The use of a multi-gene panel allowed better resolution than any constituent single gene. The method was precise, correlated well with Affymetrix microarray data, and could be easily scaled up for high-throughput. CONCLUSION: This method provides a generic solution for high-throughput differentiation screens in primary human T cells where no single-gene or functional assay is available. This screening platform will allow the identification of small molecules, genes or soluble factors that direct memory differentiation in naive human lymphocytes.


Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Galectina 3/inmunología , Perfilación de la Expresión Génica , Memoria Inmunológica/genética , Linfocitos T CD4-Positivos/metabolismo , Técnicas de Cultivo de Célula , Diferenciación Celular/inmunología , Galectina 3/genética , Humanos , Separación Inmunomagnética , Técnicas de Amplificación de Ácido Nucleico , Análisis de Secuencia por Matrices de Oligonucleótidos , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/genética , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/inmunología , Receptores CCR7/genética , Receptores CCR7/inmunología , Reproducibilidad de los Resultados , Receptor fas/genética , Receptor fas/inmunología
9.
Nucleic Acids Res ; 36(Database issue): D351-9, 2008 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17947324

RESUMEN

ChemBank (http://chembank.broad.harvard.edu/) is a public, web-based informatics environment developed through a collaboration between the Chemical Biology Program and Platform at the Broad Institute of Harvard and MIT. This knowledge environment includes freely available data derived from small molecules and small-molecule screens and resources for studying these data. ChemBank is unique among small-molecule databases in its dedication to the storage of raw screening data, its rigorous definition of screening experiments in terms of statistical hypothesis testing, and its metadata-based organization of screening experiments into projects involving collections of related assays. ChemBank stores an increasingly varied set of measurements derived from cells and other biological assay systems treated with small molecules. Analysis tools are available and are continuously being developed that allow the relationships between small molecules, cell measurements, and cell states to be studied. Currently, ChemBank stores information on hundreds of thousands of small molecules and hundreds of biomedically relevant assays that have been performed at the Broad Institute by collaborators from the worldwide research community. The goal of ChemBank is to provide life scientists unfettered access to biomedically relevant data and tools heretofore available primarily in the private sector.


Asunto(s)
Bases de Datos Factuales , Evaluación Preclínica de Medicamentos , Bioensayo , Línea Celular , Fenómenos Químicos , Química , Biología Computacional , Gráficos por Computador , Internet , Preparaciones Farmacéuticas/química , Programas Informáticos , Interfaz Usuario-Computador
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA